Long Position on PRAH @ $41.20 on 3/23/2016 (Momentum)

PRA Health Sciences, Inc. (PRAH) provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide.

The company offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting.

Its services include a suite of product registration services, such as clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

The company’s services also comprise strategic solutions, including embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services, including Phase I through Phase IIa clinical trials and bioanalytical laboratory services. It conducts clinical trials in the areas of pharmaceutical development, comprising oncology, central nervous system, inflammation, and infectious diseases. 

Shares are in the process of forming a "double bottom" as shown in blue. Higher share prices are expected for this stock.

52-Weeks Trading Range: $26.91 - $50.25

Entry Point: $41.20

Stop Loss: $39.10

Target Price: $45.32

Updates

4/4/2016 11:42:37 AM

PRAH closed at $45.40.

Position closed on 4/4/2016 at price of $45.40 with a 10.19% gain in 12 days.

Back to Portfolio